# Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections

> **NCT00108433** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 61 (actual)

## Conditions studied

- Bacteremia
- Gram-Positive Bacterial Infections

## Interventions

- **DRUG:** Cefazolin IV
- **DRUG:** Linezolid IV
- **DRUG:** Vancomycin (IV)

## Key facts

- **NCT ID:** NCT00108433
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-09
- **Primary completion:** —
- **Final completion:** 2006-09
- **Target enrollment:** 61 (ACTUAL)
- **Why stopped:** See Detailed Description
- **Last updated:** 2012-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00108433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00108433, "Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00108433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*